Skip to content

Efficacy and Safety of Allogenic Stem Cell Product(CARTISTEM®) for Osteochondral Lesion of Talus

A Multi-center, Single-blind, Randomized, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Adding CARTISTEM® on Microfracture in Patients With Talar Chondral or Osteochondral Defect

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04310215
Enrollment
102
Registered
2020-03-17
Start date
2020-03-03
Completion date
2022-06-13
Last updated
2022-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chondral or Osteochondral Lesion of Talus

Keywords

OLT, Talus, Chondral Lesion, Osteochondral Lesion, Human umbilical cord blood-derived stem cell, MSC, Mesenchymal stem cell

Brief summary

The purpose of this study is to evaluate the efficacy and safety of adding CARTISTEM®(allogenic umbilical cord blood-derived stem cell product) on microfracture, a currently standard treatment for OLT, in patients with talar chondral or osteochondral defect.

Interventions

BIOLOGICALCARTISTEM®

\*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠ 1. Procedure: Microfracture 2. Biological: CARTISTEM®(Human Umbilical Cord Blood-derived Mesenchymal Stem Cell product)

PROCEDUREMicrofracture

\*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠ 1\. Procedure: Microfracture

Sponsors

Medipost Co Ltd.
CollaboratorINDUSTRY
Hyundai Bioland Co., Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Intervention model description

A multicenter, Single-blinded, Stratified randomized

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Talar chondral/osteochondral lesion confirmed by radiographical exam at screening or diagnosis, an AOFAS score of 75 or below 2. Ankle joint pain/stiffness with no response to conservative treatment for more than 12 weeks 3. Ankle joint cartilage injury of defect of ICRS grade Ⅳ in MRI 4. Male or female aged more than 18 5. A one-sided lesion 6. Appropriate function of blood clot: PT(INR) \< 1.5×ULN, aPTT \<1.5×ULN 7. Appropriate renal function: Creatinine ≤ 2.0 ㎎/㎗, Proteinuria ≤ trace 8. Appropriate hepatic function: Total bilirubin ≤ 2.0 ㎎/㎗, AST/ALT ≤ 100 IU/L 9. No evidence of auto-immune disorder: According to investigator's judgement based on relevent symtom and physical exam, anti-nuclear antibody and anti-thyroglobulin antibody tests are able to performed and confirmed negative (If positive, there are possible cases according to diagnostic opinion of medical department) 10. No surgery or radiotherapy for the same ankle joint within 6 weeks 11. Female patients agreeing with maintenance of contraception\* during study period \*hormone contraceptive, implants of intrauterine device or intrauterine system, double barrier contraception\[Concurrent use of diaphragm or cervical occlusive cap and male condom\], surgical sterilisation, etc. 12. No chronic ligament instability more than grade Ⅲ (Grade 0: none, Grade Ⅰ: 1\ 5㎜, GradeⅡ: 5\ 10㎜, Grade Ⅲ: \>10㎜) 13. Patients agreeing with participation in this study and signed on informed consent by their own will

Exclusion criteria

1. Degenerative arthritis in ankle(Kellgren Lawrence Grade 3-4) 2. Autoimmune disease 3. Infectious disease need to administration of parenteral antibiotics 4. Myocardial infarction, congestive heart failure, other serious cardiac disorder or uncontrolled resistant hypertension 5. Serious medical disease(Ex. Kidney disease such as chronic renal failure or Glomerulonephritis, etc., acute/chronic liver disease such as liver cirrhosis, fatty liver etc., medical history of malignancy\*) \*Complete remission status is possible. 6. Pregnancy or breast-feeding 7. Psychiatric history or epilepsy 8. Alcohol abuse 9. Heavy smoker 10. Chronic inflammatory disease such as rheumatoid arthritis 11. Participants other clinical trials within 4 weeks 12. Administration of immunosuppressing agents such as Cyclosporin A or azathioprine within 6 weeks 13. Patients with acute ligament injury and clinically significant chronic ligament instability 14. Patients treated with surgery or cell therapy product for the same disease 15. Patients with hypersensitivity or allergy history to bovine protein, hyaluronic acid and gentamicin 16. Other inappropriate patients determined by the principal investigator

Design outcomes

Primary

MeasureTime frameDescription
ICRS-Cartilage Repair Assessment Total ScoreWeek 48Arthroscopic evaluation of articular cartilage repair : The score range from 12(normal) to 1(severely abnormal) where lower scores indicate more severity of injury

Secondary

MeasureTime frameDescription
ICRS-Cartilage Repair Assessment Overall GradeWeek 48The grades range from 1(normal) to 4 (severely abnormal) where lower grades indicate more complete repair
Improvement degree of Cartilage Repair by MRIWeek 0 and 48Changes in MOCART(Magnetic resonance Observation of Cartilage Repair Tissue) score : MOCART score is a 9-part and 29-item scoring system, also resulting in a find cartilage repair tissue score between 0 and 100 points. 100 points represent the best imaginable score
Degree of Functional improvement in FAOS(Foot & Ankle Outcome Score)Week 0, 24 and 48: FAOS consists in 42 items that cover 5 dimensions (symptoms, pain, activities of daily living, sport and recreation activities, and quality of life. Raw scores of each sub-scales results of the sum of each items. A normalized score (100 indicationg no symptoms and 0 indicating extreame sysmptoms) is calculated for each subscale
Degree of Functional improvement in AOFAS(The American Orthopaedic Foot & Ankle Score)Week 0, 24 and 48: AOFAS consists in 9 items that can be divided into 3 sub-scales (pain, function and alignment). 100 points of 1 to 100 represent no symptoms or impairments
Degree of Functional improvement in Tegner activity scoreWeek 0, 24 and 48: Tegner activity represents the highest level of activity on scale of 0 to 10 that you are able to participate in currently . The higher values represent a better outcome
Degree of Quality of Life improvement in SF-36(Short Form Health Survey-36)Week 0, 24 and 48: SF-36 comprises 36 items divided into two components of physical health and mental health. Higher scores between 0 and 100 represent better health status
Degree of pain improvement in 100 mm VAS(Visual Analogue Scale)Week 0, 24 and 48* VAS represents higher scores mean higher pain * 0 mm (no pain) and 100 mm (worst pain)

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026